Abstract
Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+). This review discusses recent evidence that shows PO acts via the multiple inositol polyphosphate phosphatase (MIPP) to regulate gene expression. As a consequence, PO inhibition causes both a transient, rapid increase in I(1,4,5)P3 and a long-term elevation of IP signalling. This pathway is evolutionary conserved, being present in both the social amoeba Dictyostelium and human cell systems, and has potential implications for mental health.
Keywords: Bipolar mood disorder, Dictyostelium, inositol phosphate signalling, lithium, multiple inositol polyphosphate phosphatase, prolyl oligopeptidase, IMPase, LY294002, GSK-3, MIPP, ISYNA1
CNS & Neurological Disorders - Drug Targets
Title: Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity
Volume: 10 Issue: 3
Author(s): Adrian J. Harwood
Affiliation:
Keywords: Bipolar mood disorder, Dictyostelium, inositol phosphate signalling, lithium, multiple inositol polyphosphate phosphatase, prolyl oligopeptidase, IMPase, LY294002, GSK-3, MIPP, ISYNA1
Abstract: Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+). This review discusses recent evidence that shows PO acts via the multiple inositol polyphosphate phosphatase (MIPP) to regulate gene expression. As a consequence, PO inhibition causes both a transient, rapid increase in I(1,4,5)P3 and a long-term elevation of IP signalling. This pathway is evolutionary conserved, being present in both the social amoeba Dictyostelium and human cell systems, and has potential implications for mental health.
Export Options
About this article
Cite this article as:
J. Harwood Adrian, Prolyl Oligopeptidase, Inositol Phosphate Signalling and Lithium Sensitivity, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653779
DOI https://dx.doi.org/10.2174/187152711794653779 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mitochondrially-Targeted Therapeutic Strategies for Alzheimer’s Disease
Current Alzheimer Research Quantitative Characterization of Phenotypical Markers After Differentiation of SH-SY5Y Cells
CNS & Neurological Disorders - Drug Targets Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) Targets of 3-Bromopyruvate, A New, Energy Depleting, Anticancer Agent
Medicinal Chemistry Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets Mitochondrial Permeability Transition as Target of Anticancer Drugs
Current Pharmaceutical Design Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology The Role of Iron Toxicity in Oxidative Stress-induced Cellular Degeneration in Down Syndrome: Protective Effects of Phenolic Antioxidants
Current Nutrition & Food Science Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets
Infectious Disorders - Drug Targets Synthesis of Some Coumarinyl Chalcones and their Antiproliferative Activity Against Breast Cancer Cell Lines
Letters in Drug Design & Discovery Multi-Classifier Based on Hard Instances- New Method for Prediction of Human Immunodeficiency Virus Drug Resistance
Current Topics in Medicinal Chemistry